<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088514</url>
  </required_header>
  <id_info>
    <org_study_id>10/H0703/98</org_study_id>
    <nct_id>NCT03088514</nct_id>
  </id_info>
  <brief_title>Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ Damage</brief_title>
  <acronym>NITRATE-TOD</acronym>
  <official_title>Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether dietary inorganic nitrate (in beetroot juice) is able to&#xD;
      reduce overall thickening of the heart (left ventricular hypertrophy or LVH) and stiffness of&#xD;
      the arteries when given to patients with persistently raised blood pressure (hypertension).&#xD;
      Half the patients will receive the beetroot juice containing inorganic nitrate and half will&#xD;
      receive beetroot juice from which the inorganic nitrate has been removed. The volunteers will&#xD;
      take the juice every day for 4 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In hypertension persistent raised blood pressure (BP) is associated with endothelial&#xD;
      dysfunction, arterial stiffness and left ventricular (LV) remodeling that are key phenomena&#xD;
      associated with the pathogenesis and complications of hypertension.&#xD;
&#xD;
      One of the main substances that the healthy endothelium produces that is responsible for&#xD;
      maintaining the patency of blood vessels is nitric oxide (NO). In hypertension, one of the&#xD;
      key pathogenic effects is the dysfunction of the endothelium characterized by a decrease in&#xD;
      ability to generate nitric oxide (NO). Previous studies have shown that dietary inorganic&#xD;
      nitrate supplementation lowers blood pressure (Kapil et al. 2015), however, whether this&#xD;
      approach might also improve endothelial function and LV remodeling is unknown. The effects of&#xD;
      inorganic nitrate are due to its conversion in the body to inorganic nitrite and thereafter&#xD;
      to NO.&#xD;
&#xD;
      This study will assess the effects of dietary inorganic nitrate on LVH using cardiac magnetic&#xD;
      resonance imaging (NITRATE-LVH arm). In addition, the effects of dietary inorganic nitrate on&#xD;
      central aortic blood pressure, arterial stiffness using pulse wave velocity and endothelial&#xD;
      function using flow mediated dilatation will be evaluated (NITRATE-CBP arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular hypertrophy regression</measure>
    <time_frame>4 months</time_frame>
    <description>change in LV mass as assessed using cardiac magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>4 months</time_frame>
    <description>non-invasive measures of arterial stiffness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central blood pressure</measure>
    <time_frame>4 months</time_frame>
    <description>non-invasive measure of central blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow mediated dilatation (FMD)</measure>
    <time_frame>4 months</time_frame>
    <description>non-invasive measure of endothelial function using ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial blood pressure</measure>
    <time_frame>4 months</time_frame>
    <description>brachial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma nitrate levels</measure>
    <time_frame>4 months</time_frame>
    <description>assessed by chemiluminescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma nitrite levels</measure>
    <time_frame>4 months</time_frame>
    <description>assessed by chemiluminescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nitric oxide activity (cGMP)</measure>
    <time_frame>4 months</time_frame>
    <description>nitric oxide activity measured by determining plasma concentrations of cyclic guanosine monophosphate (cGMP)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>NITRATE-LVH intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NITRATE-LVH placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70ml of beetroot juice (no inorganic nitrate) once a day for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NITRATE-CBP intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NITRATE-CBP placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70ml of beetroot juice (no inorganic nitrate) once a day for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beetroot juice</intervention_name>
    <description>Beetroot juice (70ml daily) with or without inorganic nitrate</description>
    <arm_group_label>NITRATE-CBP intervention</arm_group_label>
    <arm_group_label>NITRATE-CBP placebo</arm_group_label>
    <arm_group_label>NITRATE-LVH intervention</arm_group_label>
    <arm_group_label>NITRATE-LVH placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients will be enrolled following an informed consent. The subject will be able to&#xD;
             understand and comply with protocol requirements, instructions and protocol&#xD;
             restrictions.&#xD;
&#xD;
          2. Aged 18-80 years.&#xD;
&#xD;
          3. The study subjects will be hypertensives with evidence of difficulty treating to&#xD;
             target BP (daytime ABPM 135-170/85-105 mmHg) on 1 or more antihypertensive agents,&#xD;
             with insufficient efficacy or intolerance of medications.&#xD;
&#xD;
          4. For NITRATE LVH, echocardiographic evidence of LV hypertrophy (LV mass indexed to body&#xD;
             surface area (BSA); males &gt;115g/m2; females &gt;95 g/m2).&#xD;
&#xD;
          5. Patients will have been established on an antihypertensive treatment regime for at&#xD;
             least 1 month by the time of participation in the study and will not require changes&#xD;
             in pharmacological intervention for the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Unless specified, a subject will not be eligible for inclusion in this study if any of the&#xD;
        following criteria apply:&#xD;
&#xD;
          1. History of chronic viral hepatitis (including presence of hepatitis B surface antigen&#xD;
             or hepatitis C antibody), or other chronic hepatic disorders.&#xD;
&#xD;
          2. History of increased liver function tests (ALT, AST) due to acute or chronic liver&#xD;
             conditions, 3x above the upper limit of normal or bilirubin 1.5x above the upper limit&#xD;
             of normal at screening.&#xD;
&#xD;
          3. Renal impairment with creatinine clearance (eGFR) of &lt;50 ml/min at screening.&#xD;
&#xD;
          4. Patients with diabetes mellitus, defined by previous history of diabetes or HbA1c&#xD;
             &gt;6.5% (&gt;48 mmol/mol) at screening.&#xD;
&#xD;
          5. Subjects with LDLc, &gt;7.5 mmol/l. TG level &gt;10mmol/l.&#xD;
&#xD;
          6. History of heart failure defined as NYHA class II - IV or those with known LV&#xD;
             dysfunction (EF&lt;40%) regardless of symptomatic status&#xD;
&#xD;
          7. History of malignancy within the past 5 years, other than non-melanoma skin cancer.&#xD;
&#xD;
          8. Current life-threatening condition other than vascular disease (e.g. very severe&#xD;
             chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent&#xD;
             a subject from completing the study.&#xD;
&#xD;
          9. Use of an investigational device or investigational drug within 30 days or 5&#xD;
             half-lives (whichever is longer) preceding the first dose of study medication.&#xD;
&#xD;
         10. Subjects who will commence or who are likely to commence regular treatment with&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs) (other than aspirin), from screening&#xD;
             until study completion.&#xD;
&#xD;
         11. Any non-stable dosing of ongoing medication regimens throughout the study trial.&#xD;
&#xD;
         12. Drug abuse within the past 6 months.&#xD;
&#xD;
         13. The subject has a three-month prior history of regular alcohol consumption exceeding&#xD;
             an average weekly intake of &gt; 28 units (or an average daily intake of greater than 3&#xD;
             units) for males, or an average weekly intake of &gt; 21 units (or an average daily&#xD;
             intake of greater than 2 units) for females. 1 unit is equivalent to a half-pint&#xD;
             (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine.&#xD;
&#xD;
         14. Any other subject whom the Investigator deems unsuitable for the study (e.g. due to&#xD;
             other medical reasons, laboratory abnormalities, expected study medication&#xD;
             noncompliance, or subject's unwillingness to comply with all study-related study&#xD;
             procedures).&#xD;
&#xD;
         15. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions&#xD;
             known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).&#xD;
&#xD;
         16. Subjects with any acute infection, or recent systemic (oral or IV) antibiotics within&#xD;
             1 month of screening, or significant trauma (burns, fractures).&#xD;
&#xD;
         17. Subjects who have donated more than 500 mL of blood within 56 days prior to the study&#xD;
             medication administration.&#xD;
&#xD;
         18. Self reported use of anti-microbial mouthwash or tongue scrapes.&#xD;
&#xD;
         19. Concomitant xanthine oxidase inhibitors (such as allopurinol).&#xD;
&#xD;
         20. Known history of significant claustrophobia, previous intolerance of CMR imaging or&#xD;
             known (or suspected) incompatible metallic implant.&#xD;
&#xD;
         21. Pregnancy.&#xD;
&#xD;
         22. Allergy to gadolinium-based contrast agents used for CMR.&#xD;
&#xD;
         23. Patients with known LVH caused by another established pathology diagnosed prior to or&#xD;
             at screening e.g. severe aortic stenosis, hypertrophic cardiomyopathy, amyloidosis and&#xD;
             Fabry's disease.&#xD;
&#xD;
        Exceptions to the exclusion criteria:&#xD;
&#xD;
          -  For criteria 18, patients can enter the trial if they discontinue the use of&#xD;
             anti-microbial mouthwash for the duration of the clinical trial.&#xD;
&#xD;
          -  nCriteria 20 and 22 do not apply to participants who will not have a CMR scan in the&#xD;
             NITRATE-CBP arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Ahulwalia, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amrita Ahulwalia, BSc PhD</last_name>
    <phone>02078825720</phone>
    <email>a.ahluwalia@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clement Lau, MBChB (Hons)</last_name>
    <phone>02078825720</phone>
    <email>c.lau@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary University of London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clement Lau, MBChB (Hons)</last_name>
      <email>c.lau@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Amrita Ahulwalia, BSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vikas Kapil, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Moon, MB BCh MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clement Lau, MBChB (Hons)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krishnaraj Rathod, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asad Shabbir, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Primus, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ceri Davies, MBBS MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Mathur, FRCP PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015 Feb;65(2):320-7. doi: 10.1161/HYPERTENSIONAHA.114.04675. Epub 2014 Nov 24.</citation>
    <PMID>25421976</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary University of London</investigator_affiliation>
    <investigator_full_name>Amrita Ahluwalia</investigator_full_name>
    <investigator_title>Professor of Vascular Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Left Ventricular Hypertrophy</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Nitrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

